awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38946563-151BC544-A30B-44A7-AB8B-390B1338DEAD
Q38946563-151BC544-A30B-44A7-AB8B-390B1338DEAD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38946563-151BC544-A30B-44A7-AB8B-390B1338DEAD
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
P2860
Q38946563-151BC544-A30B-44A7-AB8B-390B1338DEAD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38946563-151BC544-A30B-44A7-AB8B-390B1338DEAD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
62f7667d85977573e39ef0fd8abefcd8f2e0843c
P2860
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.